Johnson & Johnson (JNJ)
3 Dividend Growth Stocks to Accumulate on Dips: August Edition
Dividend-paying stocks are ideal for outperforming the market or generating passive income. Finding dividend growth stocks, companies that have shown the ability and willingness to raise their distributions over time, providing consistent and growing income to investors, are even more valuable, particularly in this current market.
3 Defensive Stocks Weathering the Market Storm
In a week where fear, uncertainty, and widespread selling swept the market, three stocks stood out for their resilience: Johnson & Johnson NYSE: JNJ, Coca-Cola NYSE: KO, and Procter & Gamble NYSE: PG.
3 stocks to counter a recession, according to ChatGPT4-o
The most recent U.S. jobs report published on Friday, August 2, gave investors a fright, as evidenced by the massive bloodbath in both the stock market and across the cryptocurrency markets, with the flagship digital asset Bitcoin (BTC) now struggling to stay above $50,000.
RETRANSMISSION: Preclinical and Clinical Pharmacokinetic, Pharmacodynamic, and Safety Data of Targeted Oral Peptide JNJ-2113 Published in Scientific Reports
NEWARK, CA / ACCESSWIRE / August 1, 2024 / Protagonist Therapeutics, Inc. ("Protagonist" or the "Company") today announced publication of preclinical and phase 1 clinical data on JNJ-2113 in the journal Scientific Reports, a Nature publication and the 5th most-cited journal in the world, according to the publisher. A link to the publication can be found HERE.
Preclinical and Clinical Pharmacokinetic, Pharmacodynamic, and Safety Data of Targeted Oral Peptide JNJ-2113 Published in Scientific Reports
NEWARK, CA / ACCESSWIRE / August 1, 2024 / Protagonist Therapeutics, Inc. ("Protagonist" or the "Company") today announced publication of preclinical and phase 1 clinical data on JNJ-2113 in the journal Scientific Reports, a Nature publication and the 5th most-cited journal in the world, according to the publisher. A link to the publication can be found HERE.
Top 2 Cheap Healthcare Stocks to Buy as Sector Outperforms
As the second half of the year has gotten underway, the healthcare sector, represented by the XLV ETF, has seen a notable resurgence. This sector, which had been underperforming since the pandemic, is now breaking out of a multi-year consolidation phase.
Could Johnson & Johnson's Troubles With Talc Lawsuits Finally Be Coming to an End?
Johnson & Johnson is attempting to resolve talc lawsuits through bankruptcy for a third time. This time around, it's letting claimants vote on its proposed settlement.
How Should You Play J&J (JNJ) Stock After Q2 Earnings Beat?
Though J&J (JNJ) beat estimates for both earnings and sales in the second quarter, a new investor should avoid buying the stock right now due to its legal troubles.
Johnson & Johnson (JNJ) is Attracting Investor Attention: Here is What You Should Know
Johnson & Johnson (JNJ) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.
4 Positives For Johnson & Johnson
Johnson & Johnson might be the worst performing big pharma stock YTD, but there's upside possible for it in the remainder of 2024. Revenue growth guidance was upgraded and even with a downgrade in EPS guidance, the number is still expected to see a YoY increase. Its market multiples indicate the possibility of some uptick, and there are dividends to consider too.
Johnson & Johnson: Seriously Undervalued At Peak Pessimism
Johnson & Johnson, the pharmaceutical giant with a 3.21% dividend yield, released financial results for Q2 2024 that exceeded my expectations. Its oncology franchise revenue was $5.09 billion for the three months ended June 30, 2024, an increase of 15.7% year-on-year. For example, sales of Darzalex, an anticancer medication, were $2.88 billion in the second quarter of 2024, up 18.4% year-on-year.
Should You Pick Johnson & Johnson Stock At $155 After Q2 Beat?
Johnson & Johnson (NYSE: JNJ) recently reported its Q2 results, with revenues aligning and earnings exceeding our estimates. The company reported revenue of $22.4 billion and adjusted earnings of $2.82 per share, compared to our estimates of $22.5 billion and $2.72, respectively.
